Lars Anders
Impact in
- Oncology top 5%
- Cancer-related Molecular Pathways
- Molecular Biology top 10%
- Genomics and Chromatin Dynamics
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- RNA Research and Splicing
Papers in
-
- Protein Degradation and Inhibitors 3
- Genomics and Chromatin Dynamics 3
- Ubiquitin and proteasome pathways 2
- Epigenetics and DNA Methylation 1
- Oncology 6
- Cancer-related Molecular Pathways 4
- Co-authors
- Yoojin Choi (1 shared paper)Richard A. Young (5 shared papers)Piotr Siciński (3 shared papers)Yoon Jong Choi (2 shared papers)Per Hydbring (2 shared papers)Hans R. Widlund (1 shared paper)Stephen P. Gygi (1 shared paper)Marc Vidal (1 shared paper)
- Journals
- Cancer Research (3 papers)Diabetes (1 paper)Nature Biotechnology (1 paper)Oncogene (1 paper)Cancer Cell (1 paper)
- Partner nations
- United StatesGermanySingapore
In The Last Decade
Lars Anders
13 papers receiving 1.6k citations
Lars Anders's Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 459
- Molecular Biology 1.1k
- Cancer Research 207
- Hematology 132
- Pulmonary and Respiratory Medicine 304
Countries citing papers authored by Lars Anders
This map shows the geographic impact of Lars Anders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Anders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Anders more than expected).
Fields of papers citing papers by Lars Anders
This network shows the impact of papers produced by Lars Anders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Anders. The network helps show where Lars Anders may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Anders, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element Hit paper breakdown → | 2014 | 562 |
| 2 | A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells Hit paper breakdown → | 2011 | 450 |
| 3 | 2013 | 240 | |
| 4 | 2014 | 145 | |
| 5 | 2006 | 89 | |
| 6 | 2014 | 49 | |
| 7 | 2023 | 45 | |
| 8 | 2014 | 24 | |
| 9 | 2024 | 7 | |
| 10 | 2024 | 2 | |
| 11 | 2016 | 1 | |
| 12 | 2013 | 1 | |
| 13 | 2024 | 1 |
About Lars Anders
Lars Anders is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cell Biology and Physiology, having authored 13 papers that have together received 1.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (5 papers), Cancer-related Molecular Pathways (4 papers), Protein Degradation and Inhibitors (3 papers), Genomics and Chromatin Dynamics (3 papers), Ubiquitin and proteasome pathways (2 papers), Microtubule and mitosis dynamics (2 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Epigenetics and DNA Methylation (1 paper). The work is most often cited by research in Oncology (459 citations), Molecular Biology (1.1k citations), Cancer Research (207 citations), Hematology (132 citations) and Pulmonary and Respiratory Medicine (304 citations). Lars Anders has collaborated with scholars based in United States, Germany and Singapore. Frequent co-authors include Yoojin Choi, Richard A. Young, Piotr Siciński, Yoon Jong Choi, Per Hydbring, Hans R. Widlund, Stephen P. Gygi, Marc Vidal, Nan Rosemary Ke and Huili Zhai. Their work appears in journals such as Cancer Research, Diabetes, Nature Biotechnology, Oncogene and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.